Lipigon Pharmaceuticals AB (publ) (FRA:9RP)

Market Cap	446.00K
Revenue (ttm)	119.12K
Net Income (ttm)	-3.25M
Shares Out	n/a
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.0010
Previous Close	0.0010
Day's Range	0.0010 - 0.0010
52-Week Range	0.0001 - 0.0241
Beta	n/a
RSI	19.97
Earnings Date	Feb 20, 2026

About FRA:9RP

Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company’s product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based i...

• Industry: Pharmaceutical Preparations
• Founded: 2010
• Employees: 7
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 9RP

Financial Performance

In 2024, FRA:9RP's revenue was 10.29 million, a decrease of -37.30% compared to the previous year's 16.41 million. Losses were -25.26 million, 108.3% more than in 2023.

Financial numbers in SEK